147 related articles for article (PubMed ID: 34756245)
1. Bone marrow microenvironment of MPN cells.
Malara A; Di Buduo CA; Abbonante V; Balduini A
Int Rev Cell Mol Biol; 2021; 365():71-96. PubMed ID: 34756245
[TBL] [Abstract][Full Text] [Related]
2. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.
Leimkühler NB; Gleitz HFE; Ronghui L; Snoeren IAM; Fuchs SNR; Nagai JS; Banjanin B; Lam KH; Vogl T; Kuppe C; Stalmann USA; Büsche G; Kreipe H; Gütgemann I; Krebs P; Banz Y; Boor P; Tai EW; Brümmendorf TH; Koschmieder S; Crysandt M; Bindels E; Kramann R; Costa IG; Schneider RK
Cell Stem Cell; 2021 Apr; 28(4):637-652.e8. PubMed ID: 33301706
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
[TBL] [Abstract][Full Text] [Related]
5. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
6. [Bone marrow pathology of myeloproliferative neoplasms].
Ito M
Rinsho Ketsueki; 2015 Aug; 56(8):956-62. PubMed ID: 26345553
[TBL] [Abstract][Full Text] [Related]
7. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
8. Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
Guo BB; Linden MD; Fuller KA; Phillips M; Mirzai B; Wilson L; Chuah H; Liang J; Howman R; Grove CS; Malherbe JA; Leahy MF; Allcock RJ; Erber WN
Br J Haematol; 2020 Jan; 188(2):272-282. PubMed ID: 31426129
[TBL] [Abstract][Full Text] [Related]
9. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
Jutzi JS; Mullally A
Front Immunol; 2020; 11():2093. PubMed ID: 32983162
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.
Malherbe JA; Fuller KA; Arshad A; Nangalia J; Romeo G; Hall SL; Meehan KS; Guo B; Howman R; Erber WN
J Clin Pathol; 2016 Feb; 69(2):155-63. PubMed ID: 26290261
[TBL] [Abstract][Full Text] [Related]
11. JAK2
Zhan H; Ma Y; Lin CH; Kaushansky K
Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
[TBL] [Abstract][Full Text] [Related]
12.
Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson AS; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellström-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
Blood Adv; 2018 Mar; 2(5):534-548. PubMed ID: 29514790
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.
Limberger KA; Bogatyreva L; Todorova R; Herde B; Hauschke D; Pahl HL; Werner M; Aumann K
Histochem Cell Biol; 2017 Jan; 147(1):75-82. PubMed ID: 27544663
[TBL] [Abstract][Full Text] [Related]
14. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
[TBL] [Abstract][Full Text] [Related]
15. Aberrant proplatelet formation in chronic myeloproliferative neoplasms.
Muth M; Büsche G; Bock O; Hussein K; Kreipe H
Leuk Res; 2010 Nov; 34(11):1424-9. PubMed ID: 20430444
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
17. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
19. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
20. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
